Wytwarzanie produktów leczniczych jest dla nas nie tylko kwestia wykonania pewnego procesu technologicznego, ale misją związaną z człowiekiem opartą na wysokim standardzie jakości, bezpieczeństwa i skuteczności leków.
Mamy aktywną i kluczową rolę w podnoszeniu standardów życia codziennego. Sprawiamy, że społeczeństwo jest lepiej poinformowane, zdrowsze, szczęśliwsze i bezpieczniejsze
Sofia, Bulgaria, December 18, 2019 - Sopharma AD (3JR: “BSE-Sofia” AD, SPH: Warsaw Stock Exchange) notifies that on December 17, 2019 the Company bought 28 390 own shares representing 0.0211% of the share capital of the Company, at a total value of 98 346,20 BGN on the Bulgarian Stock Exchange, the average price per share was 3.4641 BGN. The total number of treasury shares after this transaction is 9 110 667, representing 6.76% of the share capital of the Company.
Sofia, Bulgaria, December 17, 2019 - Sopharma AD notifies that on December 16, 2019 the Company bought 30 197 own shares representing 0.0224%of the share capital of the Company, at a total value of 104 381,63 BGN
Sofia, Bulgaria, December 16, 2019 - Sopharma AD notifies that on December 13, 2019 the Company bought 14 760 own shares representing 0.0109% of the share capital of the Company, at a total value of 50 922 BGN on the Bulgarian Stock Exchange, the average price per share was 3.45 BGN.
The total number of treasury shares after this transaction is 9 052 080, representing 6.715% of the share capital of the Company.
Sofia, Bulgaria, December 13, 2019 - Sopharma AD notifies that on December 12, 2019 the Company bought 46 320 own shares representing 0.0307%of the share capital of the Company, at a total value of 142 442,436 BGN
Sofia, Bulgaria, December 13, 2019 - Sopharma AD notifies all shareholders of the Company about the decision of the EGM of Sopharma AD that took place on December 13, 2019 regarding the amount and type of dividend distributed and the terms and conditions for its distribution: